Future Medicine Ltd, Aug 2010, Pages: 92
in head and neck cancer, gene mutation in colorectal and non-small cell lungcancer, and epigenetic aberrations. EDITORIAL:
- Today’s discoveries to tomorrow’s care: cancer biomarkers revisited
CJ Rosser
Decision Resources, Inc., May 2007, Pages: 39
revenues in 2007. Competition is on the way, however. Which companies have drugs in Phase III trials for non-small-cell lungcancer? What are Genentech/Roche’s strategies for expanding their prolific
Business Insights, July 2007, Pages: 128
innovatives in 2006, supplemented by novel chemotherapeutics, hormonals and targeted therapies.
- Ten ‘blockbuster’ drugs are likely to emerge in cancer therapy over the next decade as recent and impending
John Wiley and Sons Ltd, Nov 2008, Pages: 424
.4 Acknowledgement
12. Target-directed drug discovery (Tracey Bradshaw)
12.1 Introduction
12.2 Tyrosine kinases - role and significance in cancer
12.3 Targeted therapy for the treatment of non-small cell lungcancer
Decision Resources, Inc., Feb 2008, Pages: 35
Need to Shape Your Strategy
In December 2007, Panacea’s LC Detect for early lungcancer diagnosis was named one of Time Magazine’s Top 10 Medical Breakthroughs of 2007. What other biomarker-based tests
